SCYNEXIS (SCYX) Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for SCYNEXIS in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SCYX shares.
View SCYX analyst ratings or view top-rated stocks.

3 Wall Street research analysts have issued 1-year target prices for SCYNEXIS's shares. Their SCYX share price forecasts range from $8.00 to $15.00. On average, they predict the company's share price to reach $10.50 in the next twelve months. This suggests a possible upside of 303.8% from the stock's current price.
View analysts price targets for SCYX or view top-rated stocks among Wall Street analysts.

SCYNEXIS's stock was trading at $1.56 at the start of the year. Since then, SCYX shares have increased by 66.7% and is now trading at $2.60.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our SCYX earnings forecast.

SCYNEXIS, Inc. (NASDAQ:SCYX) announced its quarterly earnings data on Friday, March, 31st. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.50) by $0.21. The business had revenue of $1.52 million for the quarter, compared to analyst estimates of $1.28 million. SCYNEXIS had a negative net margin of 1,648.61% and a negative trailing twelve-month return on equity of 875.77%.

Shares of SCYNEXIS reverse split on the morning of Friday, July 17th 2020. The 1-10 reverse split was announced on Thursday, July 16th 2020. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 16th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other SCYNEXIS investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Sorrento Therapeutics (SRNE), Gran Tierra Energy (GTE), KushCo (KSHB), Zosano Pharma (ZSAN), Bionano Genomics (BNGO), Outlook Therapeutics (OTLK), Cogent Biosciences (UMRX) and Aeterna Zentaris (AEZS).

SCYNEXIS trades on the NASDAQ under the ticker symbol "SCYX."

SCYNEXIS's stock is owned by a number of institutional and retail investors. Top institutional investors include Kingdon Capital Management L.L.C. (4.10%), AIGH Capital Management LLC (3.17%), Stonepine Capital Management LLC (1.23%), BlackRock Inc. (1.04%), D.A. Davidson & CO. (0.91%) and AMH Equity Ltd (0.75%). Insiders that own company stock include Brian Philippe Tinmouth, Eric Francois, Marco Taglietti, Perceptive Advisors Llc and Scott Sukenick.
View institutional ownership trends.

Shares of SCYX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SCYX stock can currently be purchased for approximately $2.60.

SCYNEXIS (NASDAQ:SCYX) has a market capitalization of $94.95 million and generates $5.09 million in revenue each year. The company earns $-62,810,000.00 in net income (profit) each year or ($1.93) on an earnings per share basis.

SCYNEXIS's mailing address is 1 EVERTRUST PLAZA 13TH FLOOR, JERSEY CITY NJ, 07302. The official website for the company is www.scynexis.com. The company can be reached via phone at (201) 884-5485, via email at ikoffler@lifesciadvisors.com, or via fax at 201-884-5490.